Compositions, Methods and Kits Useful for the Diagnosis and Treatment of Spinal Muscular Atrophy
Abstract
The invention relates to an isolated nucleic acid encoding a eukaryotic Survival of Motor Neuron-Interacting Protein 1 (SIP1), compositions comprising SIP1 and SIP1 and the spinal muscular atrophy (SMA) disease gene product Survival of Motor Neuron protein (SMN), and diagnostic and therapeutic assays directed to SMA. The invention also relates to another protein that specifically interacts with SMN and is a component of gems, designated Gemin3, and the nucleic acid encoding the protein. Additionally, the invention relates to a novel cell line wherein the endogenous SMN genes have been deleted and where an exogenous nucleic acid encoding SMN has been inserted into the cell such that expression of SMN in the cell is under the control of an inducible promoter. This novel cell line provides a stable genetic system for the study of SMA and for the development of SMA therapeutics.
Claims
exact text as granted — not AI-modified1 - 107 . (canceled)
108 . An antibody that specifically binds to eukaryotic Survival of Motor Neurons (SMN) polypeptide, or a fragment thereof.
109 . The antibody of claim 108 , wherein the SMN is human SMN and further wherein said antibody is monoclonal antibody 2B1.
110 . The antibody of claim 108 , wherein the SMN is chicken SMN.Join the waitlist — get patent alerts
Track US2009156789A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.